Back to Search
Start Over
Vir gains T-cell engagers from Sanofi, loses 25% of staff in another pipeline switch-up.
- Source :
- FierceBiotech; 8/2/2024, pN.PAG-N.PAG, 1p
- Publication Year :
- 2024
-
Abstract
- The "strategic restructuring" is designed to push resources into Vir's hepatitis programs "and focus on the highest near-term value opportunities." [ABSTRACT FROM AUTHOR]
- Subjects :
- HEPATITIS D
T cells
LAYOFFS
HEPATITIS
BIOTECHNOLOGY
Subjects
Details
- Language :
- English
- Database :
- Complementary Index
- Journal :
- FierceBiotech
- Publication Type :
- Periodical
- Accession number :
- 178839276